You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address